1. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005; 9:267-85.
2. Stokes A, Joutsa J, Ala-Aho R, Pitchers M, Pennington CJ, Martin C. Expression profiles and clinical correlations of degradome components in the tumor microenvironment of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2010; 16: 2022-35.
3. Blavier L, Henreit P, Imren S, Declerck YA. Tissue inhibitors of matrix metalloproteinases in cancer. Ann NY Acad Sci. 1999; 878: 108-19.
4. Cao XL
, Xu RJ
, Zheng YY
, Liu J, Teng YS, Li Y. Expression of type IV collagen, metalloproteinase-2, metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in laryngeal squamous cell carcinomas. Asian Pac J Cancer Preve. 2011; 12: 3245-9.
5. Lee KD, Lee HS, Jeon C.H. Body fluid biomarkers for early detection of Head and Neck Squamous Cell Carcinomas. Anticancer Res. 2011; 31: 1161-7.
6. Ma J, Wang J, Fan W, Pu X, Zhang D, Ch F. Upregulated TIMP-1 correlates with poor prognosis of laryngeal squamous cell carcinoma. Int J Clin Exp Pathol. 2014; 7: 246-54.
7. Mitra RS, Goto M, Lee JS, Maldonado M, Taylor JP, Pan Q. Rap1GAP promotes invasion via induction of matrix metalloproteinase 9 secretion, which is associated with poor survival in low N-stage squamous cell carcinoma. Cancer Res. 2008; 68: 3959–69.
8. Mohtasham N, Babakoohi S, Shiva A, Shadman A, Kamyab-Hesari K, Shakeri MT. Immunohistochemical study of p53, Ki-67, MMP-2 and MMP-9 expression at invasive front of squamous cell and verrucous carcinoma in oral cavity. Pathol Res Pract. 2013; 209: 110-4.
9. Rossano R, Larocca M, Riviello L, Coniglio MG, Vandooren J, Liuzzi GM. Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants. J Cell Mol Med. 2014; 18: 242-52.
10. Dünne AA, Gröbe A, Sesterhenn AM, Barth P, Dalchow C, Werner JA. Influence of matrix metalloproteinase 9 (MMP-9) on the metastatic behavior of oropharyngeal cancer. Anticancer Res. 2005; 25: 4129-34.
11. Fan HX, Li HX, Chen D, Gao ZX, Zheng JH. Changes in the expression of MMP2, MMP9, and ColIV in stromal cells in oral squamous tongue cell carcinoma: relationships and prognostic implications.J Exp Clin Cancer Res.2012;29: 31: 90.
12. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer. 2002; 95: 1902-10.
13.Rosenthal EL, Matrisian LM. Matrix metalloproteases in head and neck cancer. Head Neck. 2006; 28: 639-48.
14. Hong SD, Hong SP, Lee JI, Lim CY. Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncol. 2000; 36: 207-13.
15. Kurahara S, Shinohara M, Ikebe T, Nakamura S, Beppu M, Hiraki A. Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck. 1999; 21: 627-38.
16. Burduk PK, Bodnar M, Sawicki P, Szylberg L, Wissniewska E, Kazmierczak W et al. Expression of metalloproteinases 2 and 9 and tissue inhibitors 1 and 2 as predictors of lymph node metastases in oropharyngeal squamous cell carcinoma. Head Neck. 2015; 37: 418-22.
17. Yorioka CW, Coletta RD, Alves F, Nishimoto IN, Kowalski LP, Graner E. Matrix metalloproteinase-2 and -9 activities correlate with the disease-free survival of oral squamous cell carcinoma patients. Int J Oncol. 2002; 20: 189-94.
18. Fan H, Jiang W, Li H, Fang M, Xu Y, Zheng J. MMP-1/2 and TIMP-1/2 expression levels, and the levels of collagenous and elastic fibers correlate with disease progression in a hamster model of tongue cancer. Oncol Lett. 2016; 11: 63–8.